[go: up one dir, main page]

CO2018007221A2 - Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) - Google Patents

Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)

Info

Publication number
CO2018007221A2
CO2018007221A2 CONC2018/0007221A CO2018007221A CO2018007221A2 CO 2018007221 A2 CO2018007221 A2 CO 2018007221A2 CO 2018007221 A CO2018007221 A CO 2018007221A CO 2018007221 A2 CO2018007221 A2 CO 2018007221A2
Authority
CO
Colombia
Prior art keywords
apj
heteroarylhydroxypyrimidinones
apeline
receptor agonists
compounds
Prior art date
Application number
CONC2018/0007221A
Other languages
English (en)
Inventor
Heather Finlay
R Michael Lawrence
Michael C Myers
Wei Meng
Donna M Bilder
Zulan Pi
Robert Paul Brigance
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2018007221A2 publication Critical patent/CO2018007221A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula (I): (I) en donde todas las variables son como se definen en la memoria descriptiva, y composiciones que comprenden cualquiera de tales compuestos novedosos. Estos compuestos son agonistas de APJ que se pueden usar como medicamentos.
CONC2018/0007221A 2015-12-16 2018-07-11 Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) CO2018007221A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267997P 2015-12-16 2015-12-16
PCT/US2016/066750 WO2017106396A1 (en) 2015-12-16 2016-12-15 Heteroarylhydroxypyrimidinones as agonists of the apj receptor

Publications (1)

Publication Number Publication Date
CO2018007221A2 true CO2018007221A2 (es) 2018-07-19

Family

ID=57708840

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0007221A CO2018007221A2 (es) 2015-12-16 2018-07-11 Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)

Country Status (21)

Country Link
US (1) US10669261B2 (es)
EP (1) EP3390400B1 (es)
JP (1) JP6948322B2 (es)
KR (1) KR102742744B1 (es)
CN (1) CN108602813B (es)
AR (1) AR107061A1 (es)
AU (1) AU2016372048B2 (es)
BR (1) BR112018012112A2 (es)
CA (1) CA3008630A1 (es)
CL (1) CL2018001621A1 (es)
CO (1) CO2018007221A2 (es)
EA (1) EA036736B1 (es)
ES (1) ES2854733T3 (es)
HK (1) HK1255163A1 (es)
IL (1) IL259947B (es)
MX (1) MX380669B (es)
PE (1) PE20181487A1 (es)
SG (1) SG11201804674UA (es)
TW (1) TW201725203A (es)
UY (1) UY37026A (es)
WO (1) WO2017106396A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922401B (zh) 2015-06-03 2021-04-16 百时美施贵宝公司 用于治疗心血管病症的4-羟基-3-(杂芳基)吡啶-2-酮apj激动剂
TW201720796A (zh) 2015-10-14 2017-06-16 必治妥美雅史谷比公司 作為apj促效劑之2,4－二羥基菸鹼醯胺
JP6817305B2 (ja) 2015-12-04 2021-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アペリン受容体アゴニストおよびその使用方法
CN113636978B (zh) 2015-12-16 2024-10-29 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
ES2895124T3 (es) 2016-03-24 2022-02-17 Bristol Myers Squibb Co 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas de APJ
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
ES2863903T3 (es) 2016-06-14 2021-10-13 Bristol Myers Squibb Co 6-hidroxi-5-(fenil/heteroarilsulfonil)pirimidin-4(1H)-ona como agonistas de APJ
US10889565B2 (en) 2016-06-14 2021-01-12 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
ES2820223T3 (es) 2016-10-14 2021-04-20 Bristol Myers Squibb Co Agonistas de APJ de 3-sulfonil-5-aminopiridin-2,4-diol
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541804B1 (en) 2016-11-16 2025-01-22 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
US6174998B1 (en) 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
JPH08311041A (ja) 1995-03-16 1996-11-26 Takeda Chem Ind Ltd 複素環化合物およびその剤
CZ298812B6 (cs) 1996-07-01 2008-02-13 Dr. Reddy's Laboratories Limited Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU2001235466B2 (en) * 2000-02-16 2004-04-22 Glaxo Group Limited Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
US6943173B2 (en) 2000-07-18 2005-09-13 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
CA2522803A1 (en) 2003-04-23 2004-11-04 Pharmacia & Upjohn Company Llc Substituted pyrimidinones and pyrimidinthiones as crf antagonists
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050197327A1 (en) 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US7625912B2 (en) 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
JP4517349B2 (ja) 2004-07-28 2010-08-04 宇部興産株式会社 ピリミジン−４−オン化合物の製造方法
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
EP2016056A4 (en) 2006-04-21 2010-11-10 Univ Boston IONIC VISCOELASTIC AND VISCOELASTIC SALTS
PL2079707T3 (pl) 2006-10-10 2015-05-29 Proionic Gmbh Sposób wymiany 1,3-hetero-aromatycznych 2-karboksylanów z wodą
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
US8642778B2 (en) 2008-05-28 2014-02-04 Merck Patent Gmbh Ionic liquids
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
WO2010072696A2 (de) 2008-12-22 2010-07-01 Basf Se Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern
EP2432776B1 (en) 2009-05-21 2019-09-11 Universite Laval Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics
WO2012020742A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
US20140182680A1 (en) 2011-05-31 2014-07-03 Merck Patent Gmbh Electrolyte formulations
JP5990262B2 (ja) 2011-05-31 2016-09-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヒドリド−トリシアノ−ボラートアニオンを含む化合物
CN102903954B (zh) 2011-07-25 2015-06-03 微宏动力系统（湖州）有限公司 含有离子液体电解质的锂离子二次电池
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
AU2013271731A1 (en) 2012-06-07 2014-12-18 Georgia State University Research Foundation, Inc. SecA inhibitors and methods of making and using thereof
US9156796B2 (en) * 2012-09-21 2015-10-13 Sanofi Benzoimidazole-carboxylic acid amide derivatives as APJ receptor modulators
WO2014056844A1 (en) 2012-10-10 2014-04-17 Basf Se Ionic liquids based on oxalic acid mono esters
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
CA2890905A1 (en) 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
WO2015079028A1 (de) 2013-11-29 2015-06-04 Vtu Holding Gmbh Verrfahren zum aushärten eines klebstoffs mittels mikrowellenbestrahlung
KR101550846B1 (ko) 2014-01-29 2015-09-07 한국과학기술연구원 단일공정을 이용한 탄소소재의 다원소 도핑방법 및 그 용도
KR101531023B1 (ko) 2014-05-27 2015-06-23 한국과학기술연구원 열분해 가스 도핑에 의한 고강도 고전도성 탄소나노튜브섬유의 제조방법 및 이에 따라 제조된 탄소나노튜브섬유
US10570128B2 (en) * 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
MA39999A (fr) * 2014-06-06 2015-12-10 Res Triangle Inst Agonistes du récepteur de l'apeline (apj) et leurs utilisations
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
CN107922401B (zh) * 2015-06-03 2021-04-16 百时美施贵宝公司 用于治疗心血管病症的4-羟基-3-(杂芳基)吡啶-2-酮apj激动剂
TW201720796A (zh) 2015-10-14 2017-06-16 必治妥美雅史谷比公司 作為apj促效劑之2,4－二羥基菸鹼醯胺
JP6817305B2 (ja) 2015-12-04 2021-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アペリン受容体アゴニストおよびその使用方法
ES2895124T3 (es) 2016-03-24 2022-02-17 Bristol Myers Squibb Co 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas de APJ
US10889565B2 (en) 2016-06-14 2021-01-12 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
ES2863903T3 (es) 2016-06-14 2021-10-13 Bristol Myers Squibb Co 6-hidroxi-5-(fenil/heteroarilsulfonil)pirimidin-4(1H)-ona como agonistas de APJ
ES2820223T3 (es) 2016-10-14 2021-04-20 Bristol Myers Squibb Co Agonistas de APJ de 3-sulfonil-5-aminopiridin-2,4-diol

Also Published As

Publication number Publication date
SG11201804674UA (en) 2018-06-28
IL259947B (en) 2020-10-29
AU2016372048B2 (en) 2021-02-04
CL2018001621A1 (es) 2018-08-03
HK1255163A1 (zh) 2019-08-09
CA3008630A1 (en) 2017-06-22
CN108602813B (zh) 2021-10-29
AU2016372048A1 (en) 2018-08-02
MX380669B (es) 2025-03-12
KR102742744B1 (ko) 2024-12-12
EA201891336A1 (ru) 2019-01-31
IL259947A (en) 2018-07-31
JP6948322B2 (ja) 2021-10-13
EP3390400B1 (en) 2021-01-20
AR107061A1 (es) 2018-03-14
MX2018007155A (es) 2018-08-15
BR112018012112A2 (pt) 2018-12-04
UY37026A (es) 2017-06-30
CN108602813A (zh) 2018-09-28
TW201725203A (zh) 2017-07-16
PE20181487A1 (es) 2018-09-18
US20180362508A1 (en) 2018-12-20
US10669261B2 (en) 2020-06-02
JP2018538304A (ja) 2018-12-27
ES2854733T3 (es) 2021-09-22
EA036736B1 (ru) 2020-12-14
EP3390400A1 (en) 2018-10-24
WO2017106396A1 (en) 2017-06-22
KR20180095577A (ko) 2018-08-27

Similar Documents

Publication Publication Date Title
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CO2018011105A2 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2017002122A1 (es) Heterociclos bicíclicos como inhibidores de fgfr4
MX2020004504A (es) Derivados de fenoximetilo.
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
EA201990159A1 (ru) Биарилметильные гетероциклы
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
ECSP16074207A (es) Pirazinas moduladoras de gpr6
BR112016028948A2 (pt) ?composição bifásica?